Markt geschlossen· · EUR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
MONTPELLIER, France & CAMBRIDGE, Mass., September 23, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company") a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announced the availability of its half-year report.
MONTPELLIER, France & CAMBRIDGE, Mass., September 18, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces registration and connection details for its SENS-601 Program Day, to be held on September 22, 2026.
Sensorion (ENXTPA:ALSEN) has completed a reverse share split, exchanging every 50 existing shares for 1 new share. The consolidated stock is now trading in Paris under a new ISIN. Recent trading shows Sensorion under pressure, with the share price at €9.70 after declines of about 7% over one day, 19% over the past week and 34% across the last month. This continues a longer pattern of weak total shareholder returns over one, three and five years. This softer momentum sits alongside the new...
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.